BUZZ-Cognition Therapeutics 因阿尔茨海默氏症中期研究的积极结果而上涨

Reuters08-22 22:48

((自动化翻译由路透提供，请见免责声明 ))

8月22日 - ** 药物开发商Cognition Therapeutics 股价上涨3.7%至77美分

** 该公司报告说，其治疗阿尔茨海默病的试验性药物的中期研究取得了积极成果

** 该公司称，接受 CT1812 治疗的患者的疾病症状出现改善迹象

** 该药物显示大脑中与阿尔茨海默氏症患者认知能力下降有关的整体和相对θ功率有所改善

** CT1812 的耐受性良好，11 名 CT1812 治疗组患者和 6 名安慰剂治疗组患者出现了轻度或中度治疗相关不良事件。

** 该研究招募了16名轻度至中度阿尔茨海默病成人患者

** 包括盘中走势在内，该股今年累计下跌 57.9

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461334672?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-22 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2461334672","market":"us","top_or_hot":-1,"title":"BUZZ-Cognition Therapeutics 因阿尔茨海默氏症中期研究的积极结果而上涨","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    8月22日 - ** 药物开发商Cognition <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>   股价上涨3.7%至77美分 </p><p>** 该公司报告说，其治疗阿尔茨海默病的试验性药物的中期研究取得了积极成果 </p><p>** 该公司称，接受 CT1812 治疗的患者的疾病症状出现改善迹象 </p><p>** 该药物显示大脑中与阿尔茨海默氏症患者认知能力下降有关的整体和相对θ功率有所改善</p><p>** CT1812 的耐受性良好，11 名 CT1812 治疗组患者和 6 名安慰剂治疗组患者出现了轻度或中度治疗相关不良事件。</p><p>** 该研究招募了16名轻度至中度阿尔茨海默病成人患者 </p><p>** 包括盘中走势在内，该股今年累计下跌 57.9  </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Cognition Therapeutics 因阿尔茨海默氏症中期研究的积极结果而上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Cognition Therapeutics 因阿尔茨海默氏症中期研究的积极结果而上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-22 22:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    8月22日 - ** 药物开发商Cognition Therapeutics   股价上涨3.7%至77美分 ** 该公司报告说，其治疗阿尔茨海默病的试验性药物的中期研究取得了积极成果 ** 该公司称，接受 CT1812 治疗的患者的疾病症状出现改善迹象 ** 该药物显示大脑中与阿尔茨海默氏症患者认知能力下降有关的整体和相对θ功率有所改善** ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2461334672","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2461334672","pubTimestamp":1724338110,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** 该研究招募了16名轻度至中度阿尔茨海默病成人患者 ** 包括盘中走势在内，该股今年累计下跌 57.9","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","CGTX":"Cognition Therapeutics, Inc","BUZZ":"VanEck Social Sentiment ETF","BK4007":"制药"},"translate_title":"BUZZ-Cognition Therapeutics Rises on Positive Results from Interim Alzheimer's Study","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"CGTX":1,"LENZ":1},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    8月22日 - ** 药物开发商Cognition Therapeutics   股价上涨3.7%至77美分 ** 该公司报告说，其治疗阿尔茨海默病的试验性药物的中期研究取得了积极成果 ** 该公司称，接受 CT1812 治疗的患者的疾病症状出现改善迹象 ** 该药物显示大脑中与阿尔茨海默氏症患者认知能力下降有关的整体和相对θ功率有所改善** CT1812 的耐受性良好，11 名 CT1812 治疗组患者和 6 名安慰剂治疗组患者出现了轻度或中度治疗相关不良事件。** 该研究招募了16名轻度至中度阿尔茨海默病成人患者 ** 包括盘中走势在内，该股今年累计下跌 57.9","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461334672"}